Acurx Pharmaceuticals Stock Faces Volatility After CDI Trial Results Release
Acurx Pharmaceuticals, a clinical-stage biopharmaceutical company at the forefront of developing a groundbreaking class of small molecule antibiotics targeting resilient bacterial infections, unveiled promising efficacy
